Refractory Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H1, 2018: Ken Research REQUEST FOR SAMPLE REPORT Buy Now Request For sample Report × Report Title Name Email Designation Phone No Comapny Name Comapny URL Country -- Please Select Your Country -- Afganistan Africa Albania Algeria Andorra Angola Anguilla Antigua and Barbuda Argentina Armenia Aruba Asia Australasia Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bonaire Bosnia Herzegovina Botswana Brazil BRICS British Virgin Islands Brunei Darussalam Bulgaria Burkina Faso Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Central and South America Chad Chile China Colombia Comoros Congo Costa Rica Cote d'Ivoire Croatia Cuba Curacao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Europe European Union Falkland Islands Faroe Islands Fiji Finland France French Guiana French Polynesia Gabon Gambia Georgia Germany Ghana Gibraltar Global Great Britain Greece Greenland Grenada Guadeloupe Guam Guatemala Guerney & Alderney Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Ivory Coast Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kosovo Kuwait Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Man (Island of) Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia Middle East Minnesota Moldova Monaco Mongolia Monserrat Montenegro Morocco Morroco Mozambique Myanmar Namibia Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue North America North Korea Norway Oman Pakistan Palau Palestine Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Qatar Reunion Romania Russia Rwanda Saint Helena Saint Lucia Saint Martin Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa Samoa (American) San Marino Sao Tome and Principe Saudi Arabia Scandinavia Senegal Serbia Seychelles Sierra Leone Singapore Sint Maarten Slovakia Slovenia Solomon (Islands) Somalia South Africa South Korea South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Islands Swaziland Sweden Switzerland Syria Taiwan Tajikistan Tanzania Thailand Timor Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Uganda Ukraine United Arab Emirates United Kingdom United States Uruguay Uzbekistan Vanuatu Vatican City Venezuela Vietnam Virgin Islands Western Sahara Yemen Zambia Zimbabwe Requirement Submit Refractory diseases are those diseases that did not respond to the treatment as has surfaced again. Relapsed chronic lymphocytic leukaemia means that the cancer did not respond to the treatment and has recurred reaching remission. Treatment for this will include chemotherapy based on its response the first time. If the disease becomes resistant to chemotherapy, other drugs are used to treat leukemia. Other treatment options include targeted therapy, surgery, radiation therapy and supportive therapy. Clinical trials are conducted in medical research labs to find better ways to prevent and treat diseases or diagnose them. They give solutions on the medical approaches suitable for certain illness to a certain group of people specifically. These trials help a great deal in making healthcare decisions. Since they answer scientific questions, these trials are required to be carried on under strict and scientific standards that protect the interests of the patients. They are also the final and the most important stage of clinical research and development. Clinical trials for drugs take place in four phases- first, they test an experimental drug on a few people and study the effects; second, they test the drug on more people than in Phase 1 which may extend up to years; third, they include many other participants to test for safety and efficacy and study the side effects deeper than in Phase 2; fourth, getting approval of the usage of drug from the relevant authority. Ken Research’s Refractory Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H1, 2018 gives an overview of the global clinical trials landscape and top-level data related to clinical trials by Regio, Country (G7 and E7), Trial Status, trial Phase, Sponsor type and End point status. The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company and all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for their non-accomplishments. It provides enrolment trends for the past five years and the latest news relating to these trials for the past three months. The companies involved in the clinical trials of Refractory Chronic Lymphocytic Leukemia are AbbVie Inc, F. Hoffmann-La Roche Ltd, Celgene Corp, Novartis AG, Johnson & Johnson, AstraZeneca Plc, Gilead Sciences Inc, GlaxoSmithKline Plc, Bristol-Myers Squibb Co and Sanofi. The report will enhance the decision- making capabilities and helps to create an effective counter strategy to gain competitive advantage. For more information, click on the link below: https://www.kenresearch.com/healthcare/pharmaceuticals/refractory-chronic-lymphocytic/154882-91.html Contact Us: Ken Research Ankur Gupta, Head Marketing & Communications sales@kenresearch.com +91 9015378249 Post Views: 4 Tags: Global Refractory Chronic Lymphocytic Leukemia Market Analysis, Global Refractory Chronic Lymphocytic Leukemia Market Growth, Global Refractory Chronic Lymphocytic Leukemia Market Outlook, Global Refractory Chronic Lymphocytic Leukemia Market Research Report, Refractory Chronic Lymphocytic Leukemia Market Forecast, Refractory Chronic Lymphocytic Leukemia Market Overview, Refractory Chronic Lymphocytic Leukemia Market Revenue, Refractory Chronic Lymphocytic Leukemia Market Size, Refractory Chronic Lymphocytic Leukemia Market Trends